The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy
Open accessAbstract
We describe that galectin-1 (gal-1) is a receptor for the angiogenesis inhibitor anginex, and that the protein is crucial for tumor angiogenesis. gal-1 is overexpressed in endothelial cells of different human tumors. Expression knockdown in cultured endothelial cells inhibits cell proliferation and migration. The importance of gal-1 in angiogenesis is illustrated in the zebrafish model, where expression knockdown results in impaired vascular guidance and growth of dysfunctional vessels. The role of gal-1 in tumor angiogenesis is demonstrated in gal-1-null mice, in which tumor growth is markedly impaired because of insufficient tumor angiogenesis. Furthermore, tumor growth in gal-1-null mice no longer responds to antiangiogenesis treatment by anginex. Thus, gal-1 regulates tumor angiogenesis and is a target for angiostatic cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Galectins: A family of animal β-galactoside-binding lectins
Barondes, S. H., Castronovo, V., Cooper, D. N. W., Cummings, R. D., Drickamer, K., Felzi, T., Gitt, M. A., Hirabayashi, J., Hughes, C., Kasai, K.-I., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90498-7 · Cited by 1,223
Research works printed but not linked: 45
- 10.1097/00000658-197203000-00014 · DOI · Paper page
- AW Griffioen, G Molema Pharmacol Rev 52, 237–268 (2000). · DOI · Paper page
- JR van Beijnum, AW Griffioen Biochim Biophys Acta 1755, 121–134 (2005).
- 10.1042/bj3540233 · doi:10.1042/bj3540233
- 10.1096/fj.02-0509fje · DOI
- 10.1016/S0304-3835(03)00015-6 · DOI
- 10.1016/S0021-9258(19)81549-1 · DOI · Paper page
- 10.1093/glycob/3.4.297 · DOI · Paper page
- 10.1016/S0304-4165(02)00310-0 · DOI · Paper page
- 10.1093/molbev/msh082 · DOI · Paper page
- 10.1016/S0300-9084(01)01289-5 · DOI · Paper page
- 10.1023/B:GLYC.0000014076.43288.89 · doi:10.1023/b:glyc.0000014076.43288.89
- 10.1038/378736a0 · DOI · Paper page
- 10.1093/nar/29.17.3595 · DOI
- 10.1016/j.bbrc.2005.06.029 · DOI
- 10.1006/dbio.2002.0711 · DOI · Paper page
- 10.1093/glycob/cwh032 · doi:10.1093/glycob/cwh032
- 10.1242/dev.119.4.1229 · DOI · Paper page
- 10.1016/S1535-6108(04)00024-8 · DOI · Paper page
- RP Dings, Y Yokoyama, S Ramakrishnan, AW Griffioen, KH Mayo Cancer Res 63, 382–385 (2003).
- 10.1007/BF00731282 · DOI
- 10.1023/A:1026584523789 · DOI
- 10.1111/j.1460-9568.2004.03802.x · DOI
- 10.1016/j.pain.2004.10.009 · doi:10.1016/j.pain.2004.10.009
- 10.1016/j.cytogfr.2005.05.002 · DOI · Paper page
- 10.1016/j.cell.2005.01.010 · DOI · Paper page
- 10.1006/dbio.1996.0257 · DOI
- 10.1016/S0002-9440(10)64959-0 · DOI · Paper page
- 10.1046/j.1471-4159.2003.02060.x · DOI
- 10.1093/carcin/bgh329 · doi:10.1093/carcin/bgh329
- 10.1038/nrc1527 · DOI · Paper page
- 10.1023/B:GLYC.0000014083.48508.6a · DOI · Paper page
- 10.1073/pnas.0409844102 · DOI
- 10.1002/jcb.240430105 · doi:10.1002/jcb.240430105
- 10.1007/BF02889955 · DOI
- 10.1002/1096-9896(2000)9999:9999<::AID-PATH730>3.0.CO;2-2 · doi:10.1002/1096-9896(2000)9999:9999<::aid-path730>3.0.co;2-2
- 10.1016/S0008-6215(00)90597-4 · DOI
- 10.1016/S0076-6879(03)01075-9 · doi:10.1016/s0076-6879(03)01075-9
- 10.1016/j.yexcr.2004.06.014 · DOI
- 10.1016/j.ijrobp.2005.04.052 · DOI
- 10.1016/0014-4827(91)90431-S · DOI
- 10.1002/1097-0061(200012)17:4<294::AID-YEA54>3.0.CO;2-5 · DOI · Paper page
- 10.1242/dev.123.1.143 · DOI · Paper page
- 10.1002/dvdy.20102 · DOI
- 10.1006/dbio.2000.9995 · DOI · Paper page
Cited by
Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives
Jankowska, E. A., von Haehling, S., Anker, S. D., Macdougall, I. C., & Ponikowski, P. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs224 · Cited by 399
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
Wu, A. A., Drake, V., Huang, H.-S., Chiu, S., & Zheng, L. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1016700 · Cited by 271
Distinct longevity mechanisms across and within species and their association with aging
Tyshkovskiy, A., Ma, S., Shindyapina, A. V., Tikhonov, S., Lee, S.-G., Bozaykut, P., Castro, J. P., Seluanov, A., Schork, N. J., Gorbunova, V., et al. (2023) · Cell · doi:10.1016/j.cell.2023.05.002 · Cited by 162
Cancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression
Tang, D., Gao, J., Wang, S., Ye, N., Chong, Y., Huang, Y., Wang, J., Li, B., Yin, W., & Wang, D. (2016) · Tumor Biology · doi:10.1007/s13277-015-3942-9 · Cited by 138
Wang, F., Sun, W., Zhang, J., & Fan, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.9973 · Cited by 115
Metadata
- Authors
- Thijssen, V. L. J. L., Postel, R., Brandwijk, R. J. M. G. E., Dings, R. P. M., Nesmelova, I., Satijn, S., Verhofstad, N., Nakabeppu, Y., Baum, L. G., Bakkers, J., Mayo, K. H., Poirier, F., & Griffioen, A. W.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-10-24
- Volume
- 103
- Issue
- 43
- Pages
- 15975-15980
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1982095943
- Cited by
- 497
- References
- 1
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. https://app.cochat.ai/papers/10.1073/pnas.0603883103
- The paper
- Thijssen, V. L. J. L., Postel, R., Brandwijk, R. J. M. G. E., Dings, R. P. M., Nesmelova, I., Satijn, S., Verhofstad, N., Nakabeppu, Y., Baum, L. G., Bakkers, J., Mayo, K. H., Poirier, F., & Griffioen, A. W. (2006). Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0603883103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
